Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379319 | 0.90 | SIGMAR1 (0.68) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL7268908 | 0.89 | SIGMAR1 (0.79) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL14116237 | 0.88 | SIGMAR1 (0.69) | SIGMAR1L3MBTL1 | |
| SCHEMBL28741993 | 0.88 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL4848450 | 0.88 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL29640479 | 0.88 | SIGMAR1 (0.77) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL13360982 | 0.86 | SIGMAR1 (0.75) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL5862113 | 0.86 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL6333442 | 0.85 | SIGMAR1 (0.73) | SIGMAR1POLBL3MBTL1 | |
| SCHEMBL21816604 | 0.85 | SIGMAR1 (0.73) | SIGMAR1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1025999-C | Imidazo [4,5-B] quinolinyloxyalkanoic acid amides with enhanced water solubility | BRISTOL MYERS SQUIBB CO (US) | 1994-09-28 | — | — | CN | claimed |
| CN-1051359-A | Improved imidazo [4, the 5-b] quinolinyloxyalkanoic acid amides of water-soluble degree | BRISTOL MYERS SQUIBB CO (US) | 1991-05-15 | — | — | CN | claimed |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7342011-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342011-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-0426180-A2 | Imidazo[4,5-b] quinolinyloxyalkanoic acid amides with enhanced water solubility | Bristol-Myers Squibb Company (US) | 1991-05-08 | — | — | EP | disclosed |
| US-4289772-A | PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273765-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | SIGMAR1 2370/4885POLB 1001/4885L3MBTL1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.